for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CymaBay Therapeutics Inc

CBAY.OQ

Latest Trade

1.67USD

Change

0.02(+1.21%)

Volume

244,967

Today's Range

1.63

 - 

1.70

52 Week Range

1.29

 - 

14.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.65
Open
1.66
Volume
244,967
3M AVG Volume
33.57
Today's High
1.70
Today's Low
1.63
52 Week High
14.00
52 Week Low
1.29
Shares Out (MIL)
68.70
Market Cap (MIL)
113.36
Forward P/E
-1.11
Dividend (Yield %)
--

Latest Developments

More

Cymabay Therapeutics Third Quarter Loss Per Share $0.38

Cymabay Reports Q2 Loss Per Share $0.35

CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CymaBay Therapeutics Inc

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry

Biotechnology & Drugs

Contact Info

7575 Gateway Blvd Ste 110

+1.510.2938800

http://www.cymabay.com/

Executive Leadership

Robert James Wills

Independent Chairman of the Board

Sujal A. Shah

President, Chief Executive Officer, Director

Charles A. McWherter

Senior Vice President, Chief Scientific Officer

Daniel Menold

Vice President - Finance

Paul T. Quinlan

General Counsel, Corporate Secretary

Key Stats

2.80 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.140

2017

-0.790

2018

-1.250

2019(E)

-1.493
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-45.90
Return on Equity (TTM)
-42.64

Latest News

Latest News

CymaBay Therapeutics scraps liver disease studies; shares plunge

CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage studies testing its experimental drug in patients with non-alcoholic steatohepatitis (NASH) and another liver disease after it observed "atypical" findings in one trial, sending shares down 76% in premarket...

BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32

* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis

* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis

* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018

BRIEF-Cymabay Reports Q4 Loss Per Share $0.11

* CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock

* CYMABAY THERAPEUTICS INC - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics publishes Seladelpar proof-of-concept study

* Cymabay Therapeutics announces the publication of the Seladelpar proof-of-concept study for primary biliary cholangitis in lancet gastroenterology and hepatology

BRIEF-CymaBay Therapeutics reports Q2 loss per share $0.31

* CymaBay reports second quarter 2017 financial results and provides corporate update

BRIEF-CymaBay announces pricing of public offering of common stock

* CymaBay announces pricing of public offering of common stock

BRIEF-Cymabay announces proposed public offering of 10.0 mln common shares

* Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar

BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar

* CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis

BRIEF-Cymabay Therapeutics files for potential mixed shelf offering of up to $100 mln

* Cymabay Therapeutics Inc files for potential mixed shelf offering of up to $100 million - sec filing Source text (http://bit.ly/2q9MuN0) Further company coverage:

BRIEF-Cymabay reports Q1 loss per share $0.20

* Cymabay reports first quarter 2017 financial results and provides corporate update

BRIEF-CymaBay reports Q4 and year end 2016 financial results

* CymaBay reports fourth quarter and year end 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up